Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation

Objective – to conduct a pharmacoeconomic analysis of using omalizumab, mepolizumab and reslizumab in the treatment of patients with uncontrolled moderate and severe atopic asthma in the healthcare setting of the Russian Federation.Materials and Methods. A pharmacoeconomic model based on clinical da...

Full description

Bibliographic Details
Main Authors: S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev
Format: Article
Language:Russian
Published: IRBIS LLC 2020-02-01
Series:Фармакоэкономика
Subjects:
Online Access:https://www.pharmacoeconomics.ru/jour/article/view/315